Comparison of Insulins Aspart and Lispro in Insulin Pumps

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to compare the glycemic control between insulins aspart and lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes using an insulin pump.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tulane University Health Sciences Center
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Lispro; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 1 Diabetes treated with a pump for at least 3 months

Exclusion Criteria:

• Pregnancy

• Plasma Creatinine > 1.2 mg/dl

• Inability to give informed consent

• HbA1c > 8%

• Known or suspected hypersensitivity to trial drugs or any of their components